18:00 – 18:15
Explora la plataforma SOPHiA DDM™ que ofrece información: Pionera en datos de salud digitales descentralizados.
Gabriela Acosta,SOPHiA GENETICS, Sales Executive LATAM
18:15 – 19:00
Libera tu flujo de datos con la innovadora solución mieloide de SOPHiA GENETICS.
Jose Maria (Chema) Belloso,SOPHiA GENETICS, Global Product Manager Heme-Onco
Travesía del usuario: Desde la toma de decisión hasta la rutina en el lab.
July Katherine Rodriguez Ariza, Fundación de Investigación Clínica Molecular Aplicada al Cáncer (FICMAC), Directora científica
19:00 – 19:30
Potencia tu análisis genómico con exomas mejorados de SOPHiA GENETICS: Una solución todo en uno para múltiples indicaciones.
Luna Rodriguez,SOPHiA GENETICS, Subject Matter Expert LATAM
19:30 – 20:30
Cocktails & Networking.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.